Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2777 | RO6953958 Wiki | 0.71 |
drug985 | Daily Monitoring Wiki | 0.71 |
drug1183 | Emotional Support Plan Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D002659 | Child Development Disorders, Pervasive NIH | 0.63 |
D065886 | Neurodevelopmental Disorders NIH | 0.50 |
D001321 | Autistic Disorder NIH | 0.47 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000717 | Autism HPO | 0.47 |
HP:0000729 | Autistic behavior HPO | 0.43 |
Navigate: Correlations HPO
There are 2 clinical trials
Conducting an initial small, controlled clinical trial to assess for therapeutic vaccine activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. Produce Antigen Presentation Memory to COVID-19 Specific Antigen. 4. Produce Trained Immunity to COVID-19 Specific Antigen. 5. Avoid Antibody-Dependent Enhancement to COVID-19 Virus.
Description: Macrophage Migration Inhibitory Factor (MMIF), assessed by ELISA Sandwich Kit
Measure: Macrophage Migration Inhibitory Factor (MMIF) Time: Duration at least 28 daysConducting an initial small, controlled clinical trial to assess for COVID-19 therapeutic vaccine activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. Produce Antigen Presentation Memory to COVID-19 Specific Antigen. 4. Produce Trained Immunity to COVID-19 Specific Antigen. 5. Avoid Antibody-Dependent Enhancement to COVID-19 Virus.
Description: Each dose of Nucleocapsid-GM-CSF contains a minimum of 50 million autologous CD54+ cells activated with Nucleocapsid-GM-CSF, suspended in 250 mL of Lactated Ringer's Injection, USP. Intravenous Injection, IV After 60 hours Test Macrophage Migration Inhibitory Factor (MMIF) If Macrophage Migration Inhibitory Factor (MMIF) is positive (+) Successful trained immunity to COVID-19 specific antigen
Measure: Test Macrophage Migration Inhibitory Factor (MMIF) Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports